Most Popular
-
1
Korea’s homegrown nanosatellite successfully launches into space
-
2
Ador CEO denies allegations, accuses Hybe of mistreating NewJeans
-
3
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
4
Nicaragua shuts down Seoul embassy
-
5
Hybe's multilabel system tested amid conflict with Ador
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
-
7
SNU profs to suspend treatment for one day
-
8
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
9
SK hynix pledges W20tr to ramp up DRAM production at home
-
10
Medical reform committee kicks off despite boycott from doctors
[THE INVESTOR] Cell therapy developer Green Cross Cell and biotechnology firm ToolGen on Aug. 22 signed a memorandum of understanding on collaborating in developing immune therapy for cancer.
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
By Choi He-suk (cheesuk@heraldcorp.com)
The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.
The companies hope to amplify T-cells’ ability to attack cancer cells.
By Choi He-suk (cheesuk@heraldcorp.com)
![[KH Explains] Korean shipbuilding stocks rally: Real growth or bubble?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/04/25/20240425050656_0.jpg&u=)
